Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27663465 | 0.90 | FFAR1 (0.50) | FFAR1SMN1; SMN2 | |
| SCHEMBL1165785 | 0.89 | NPC1 (0.48) | FFAR1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL27907309 | 0.88 | GABBR2 (0.44) | FFAR1GABBR2GABBR1 | |
| SCHEMBL4041861 | 0.87 | NPC1 (0.49) | FFAR1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1670315 | 0.86 | FFAR1 (0.62) | FFAR1 | |
| SCHEMBL7507485 | 0.85 | HPGD (0.49) | FFAR1GABBR2GABBR1ALDH1A1 | |
| SCHEMBL9554333 | 0.82 | RIPK1 (0.44) | FFAR1GABBR2GABBR1 | |
| SCHEMBL27142032 | 0.82 | SCN1A (0.58) | FFAR1GABBR2GABBR1 | |
| Hydrochloric Acid SCHEMBL28602407 | 0.81 | SCN1A (0.57) | FFAR1GABBR2GABBR1 | |
| SCHEMBL24925628 | 0.80 | GSR (0.47) | SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155568-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2020-05-21 | — | — | US | disclosed |
| US-10555952-B2 | Pharmaceutical compositions and methods for anesthesiological applications | MELT PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180303847-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2018-10-25 | — | — | US | disclosed |
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-7423172-B2 | Tyrosine derivatives as PPAR-γ-modulators | LABORATORIOS SALVAT, S.A. (ES) | 2008-09-09 | — | — | US | disclosed |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | LABORATORIES SALVAT, S.A. (ES) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | FFAR1 67/4885SMN1; SMN2 4621/4885LMNA 4048/4885 |
| US-10555952-B2 | Pharmaceutical compositions and methods for anesthesiological applications | GRIN2B, GRIN3A, GABRA5 | FFAR1 1030/4885SMN1; SMN2 3318/4885LMNA 2707/4885 |
| US-20200155568-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN2B, GRIN3A, GABRA5 | FFAR1 1030/4885SMN1; SMN2 3318/4885LMNA 2707/4885 |
| US-20180303847-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN2B, GRIN3A, GABRA5 | FFAR1 1030/4885SMN1; SMN2 3318/4885LMNA 2707/4885 |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | PPARG, PPARD, PPARA | FFAR1 107/4885SMN1; SMN2 4448/4885LMNA 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.